Digest Network How does it work
Network
/
Society
Bo
Not verified

Boehringer Ingelheim Limited

What we write about

Advertising / Marketing / Media / CommunicatiManagementMedical Health WellnessPharmaceuticalsWant ads

33 Press releases

View all press releases
19/12/2025
Pharmaceuticals
Medical Health Wellness
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0
28/11/2025
Pharmaceuticals
Medical Health Wellness
Boehringer Ingelheim announces appointment to Board of Managing Directors
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0
04/11/2025
Pharmaceuticals
Advertising / Marketing / Media / Communicati
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0
29/10/2025
Pharmaceuticals
Advertising / Marketing / Media / Communicati
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0
22/10/2025
Pharmaceuticals
Medical Health Wellness
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0
17/10/2025
Pharmaceuticals
Medical Health Wellness
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0
15/10/2025
Pharmaceuticals
Advertising / Marketing / Media / Communicati
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0
09/10/2025
Pharmaceuticals
Medical Health Wellness
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0
28/09/2025
Pharmaceuticals
Medical Health Wellness
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0
01/09/2025
Pharmaceuticals
Medical Health Wellness
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Source
Boehringer Ingelheim Limited
Issuer
GLOBENEWSWIRE
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0